trending Market Intelligence /marketintelligence/en/news-insights/trending/ZB4fa_m33C4-gmb_cg16Pw2 content esgSubNav
In This List

Kyorin Holdings to develop aTyr Pharma's lung disease drug in Japan

Blog

Insight Weekly: Recession risk persists; Banks pull back from crypto; 2022 laggard stocks rally

Blog

Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage

Blog

Insight Weekly: Inflation eases; bank M&A slows; top companies boost market share

Blog

Insight Weekly: PE firms shift strategies; bank earnings kick off; bankruptcies plummet


Kyorin Holdings to develop aTyr Pharma's lung disease drug in Japan

Kyorin Holdings Inc. and aTyr Pharma Inc. signed an agreement to develop aTyr's lung disease drug in Japan.

Under the agreement, Tokyo-based Kyorin Holdings will have exclusive right to develop and commercialize ATYR1923 in Japan.

San Diego-based aTyr, which is developing ATYR1923 to treat interstitial lung diseases, will receive an up-front payment of $8 million.

ATyr may receive up to an additional $167 million if it reaches certain development, regulatory and sales milestones. The company may also receive tiered royalties on net sales in Japan.

Kyorin will fund all research, development, regulatory, marketing and commercialization activities for ATYR1923 in Japan while aTyr will supply the drug.

Interstitial lung diseases cause scarring in lung tissue which may affect a patient's ability to breathe.